Tags

Type your tag names separated by a space and hit enter

A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk.
Nutr Cancer. 2007; 57(2):130-7.NC

Abstract

This unblinded, randomized, Phase I clinical trial was conducted to determine whether lycopene supplementation lowered serum prostate specific antigen (PSA), surrogate endpoint for prostate cancer initiation or progression, in men with elevated prostate cancer risk. Afro-Caribbean men (n=81) with high-grade prostatic intraepithelial neoplasia, atypical foci or repeated non-cancerous biopsies, ascertained in a population-based screening program, were randomized to four months intervention with 30 mg/day lycopene (Lyc-O-Mato) plus a multivitamin, or to multivitamin, only. Serum PSA and lycopene were compared at randomization, 1, and 4 mo using two-sided chi2 and t-tests for independent samples. Treatment groups were similar at baseline. Serum lycopene levels approximately doubled in the lycopene intervention group. Serum PSA declined during the first month of treatment, but returned to randomization level by month 4. The PSA response was nearly identical in both treatment groups. No adverse effects attributed to lycopene supplementation were documented. We conclude that the PSA lowering response to antioxidant supplementation observed in previous 3-wk studies in men awaiting prostatectomy may have been a transient response, perhaps not specific to lycopene. Lowering of serum PSA may not be an appropriate endpoint for the long-term studies needed to evaluate lycopene supplementation for reducing prostate cancer initiation or progression.

Authors+Show Affiliations

Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA 15261, USA. bunkerc+@pitt.eduNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial, Phase I
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Research Support, U.S. Gov't, Non-P.H.S.

Language

eng

PubMed ID

17571945

Citation

Bunker, Clareann H., et al. "A Randomized Trial of Lycopene Supplementation in Tobago Men With High Prostate Cancer Risk." Nutrition and Cancer, vol. 57, no. 2, 2007, pp. 130-7.
Bunker CH, McDonald AC, Evans RW, et al. A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutr Cancer. 2007;57(2):130-7.
Bunker, C. H., McDonald, A. C., Evans, R. W., de la Rosa, N., Boumosleh, J. M., & Patrick, A. L. (2007). A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. Nutrition and Cancer, 57(2), 130-7.
Bunker CH, et al. A Randomized Trial of Lycopene Supplementation in Tobago Men With High Prostate Cancer Risk. Nutr Cancer. 2007;57(2):130-7. PubMed PMID: 17571945.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. AU - Bunker,Clareann H, AU - McDonald,Alicia C, AU - Evans,Rhobert W, AU - de la Rosa,Noreen, AU - Boumosleh,Jocelyne Matar, AU - Patrick,Alan L, PY - 2007/6/19/pubmed PY - 2007/9/12/medline PY - 2007/6/19/entrez SP - 130 EP - 7 JF - Nutrition and cancer JO - Nutr Cancer VL - 57 IS - 2 N2 - This unblinded, randomized, Phase I clinical trial was conducted to determine whether lycopene supplementation lowered serum prostate specific antigen (PSA), surrogate endpoint for prostate cancer initiation or progression, in men with elevated prostate cancer risk. Afro-Caribbean men (n=81) with high-grade prostatic intraepithelial neoplasia, atypical foci or repeated non-cancerous biopsies, ascertained in a population-based screening program, were randomized to four months intervention with 30 mg/day lycopene (Lyc-O-Mato) plus a multivitamin, or to multivitamin, only. Serum PSA and lycopene were compared at randomization, 1, and 4 mo using two-sided chi2 and t-tests for independent samples. Treatment groups were similar at baseline. Serum lycopene levels approximately doubled in the lycopene intervention group. Serum PSA declined during the first month of treatment, but returned to randomization level by month 4. The PSA response was nearly identical in both treatment groups. No adverse effects attributed to lycopene supplementation were documented. We conclude that the PSA lowering response to antioxidant supplementation observed in previous 3-wk studies in men awaiting prostatectomy may have been a transient response, perhaps not specific to lycopene. Lowering of serum PSA may not be an appropriate endpoint for the long-term studies needed to evaluate lycopene supplementation for reducing prostate cancer initiation or progression. SN - 0163-5581 UR - https://www.unboundmedicine.com/medline/citation/17571945/A_randomized_trial_of_lycopene_supplementation_in_Tobago_men_with_high_prostate_cancer_risk_ L2 - http://www.tandfonline.com/doi/full/10.1080/01635580701274046 DB - PRIME DP - Unbound Medicine ER -